Related Experiment Video
Updated: Jun 28, 2026
09:38
A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
Published on: February 14, 2017
Extending half-life in coagulation factors: where do we stand?
1Department of Pathology and Molecular Medicine, Queen's University, Kingston, Canada. lillicrap@cliff.path.queensu.ca
Thrombosis Research
|December 4, 2008
Summary
Treating hemophilia A requires frequent infusions due to the short half-life of coagulation factor VIII (FVIII). New strategies aim to extend FVIII half-life, reducing treatment burden and improving patient quality of life.
Area of Science:
- Hematology
- Biochemistry
- Pharmacology
Background:
- Coagulation factor VIII (FVIII) and von Willebrand factor (VWF) are key proteins in hemostasis.
- Deficiencies in FVIII and VWF cause hemophilia A and von Willebrand disease, respectively.
- Current hemophilia A treatments require frequent FVIII infusions due to its short plasma half-life.
Purpose of the Study:
- To review current strategies for prolonging the half-life of FVIII.
- To discuss methods aimed at reducing infusion frequency for hemophilia A patients.
Main Methods:
- Review of existing literature and research on FVIII half-life extension.
- Analysis of various biotechnological and pharmacological approaches.
Main Results:
- Several promising strategies are under investigation to extend FVIII half-life.
- Prolonging FVIII half-life could significantly reduce treatment burden.
Conclusions:
- Extending FVIII half-life is a key goal for improving hemophilia A management.
- Reduced infusion frequency will enhance patient convenience and quality of life.
Related Concept Videos
01:09Coagulation
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
01:06Coagulation
Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
01:23Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration
Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s half-life.
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
02:42Half-life of a Reaction
The half-life of a reaction (t1/2) is the time required for one-half of a given amount of reactant to be consumed. In each succeeding half-life, half of the remaining concentration of the reactant is consumed. For example, during the decomposition of hydrogen peroxide, during the first half-life (from 0.00 hours to 6.00 hours), the concentration of H2O2 decreases from 1.000 M to 0.500 M. During the second half-life (from 6.00 hours to 12.00 hours), the concentration decreases from 0.500 M to...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.